Modulation of atypical brain activation during executive functioning in autism: a pharmacological MRI study of tianeptine

Table 2 Anatomical location and statistics for BOLD activation

Region	X	Y	Z	Cluster p value	Cluster size
GO/NO-GO task (n = 17 for both groups)
ASD placebo vs TD placebo
ASD < TD (blue)
Right postcentral cortex	58	− 19	33	0.009	144
ASD > TD (red)
Right cerebellum	29	− 67	− 40	0.02	81
Right occipital cortex	11	− 96	− 7	0.01	114
Left inferior frontal cortex/left insula	− 40	19	13	0.02	95
Right premotor cortex	43	− 7	50	0.01	111
ASD tianeptine vs TD placebo
ASD < TD (blue)
Right lingual cortex	11	− 100	− 3	0.007	45
Interaction of drug status (placebo, tianeptine) by group (ASD, TD)
Cerebellum bilaterally/limbic area
Right rostromedial frontal	25	− 19	− 20	0.008	357
Cortex/caudate/cingulate	29	59	7	0.009	376
Sustained attention task (n = 19 for both groups)
TD placebo vs ASD placebo
ASD < TD (blue)
Right Middle Temporal Cortex	61	− 7	− 7	0.02	212
Right cuneus	14	− 93	3	0.0008	1082
Left precuneus	− 4	− 63	46	0.009	747
TD placebo vs ASD tianeptine
ASD < TD (blue)
Right cuneus	14	− 93	3	0.003	385
Interaction of drug status (placebo, tianeptine) by group (ASD, TD)
Right middle temporal cortex	40	− 56	10	0.01	204
Right thalamus	7	− 11	7	0.001	502
Left middle frontal cortex	− 51	4	46	0.02	180

X, Y, Z = Peak Talairach coordinates
BOLD blood-oxygen-level-dependent, ASD Individuals with Autism Spectrum Disorder, TD Typically Developed Controls

ISSN: 2040-2392